• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ABVC BioPharma, Inc. - Common Stock (NQ:ABVC)

1.770 +0.190 (+12.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ABVC BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement
January 13, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement
January 13, 2025
FREMONT, CA - January 13, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous... 
Via TheNewswire.com
News headline image
ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related Products
January 07, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market
January 02, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024 ↗
August 14, 2024
ABVC BioPharma just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024 ↗
May 17, 2024
ABVC BioPharma just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
October 29, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
October 16, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
October 15, 2024
 
Via Benzinga
News headline image
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
August 15, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
July 09, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
July 02, 2024
FREMONT, CA - (NewMediaWire) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via NewMediaWire
News headline image
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
June 25, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
July 02, 2024
FREMONT, CA - (NewMediaWire) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via TheNewswire.com
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
June 12, 2024
FREMONT, CA - (NewMediaWire) - June 12, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via NewMediaWire
News headline image
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
May 24, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M
May 22, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M
May 15, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
May 09, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
May 09, 2024
FREMONT, CA - (NewMediaWire) - May 09, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central... 
Via TheNewswire.com
News headline image
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗
April 24, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
April 23, 2024
 
Via Benzinga
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
April 18, 2024
FREMONT, CA - (NewMediaWire) - April 18, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via TheNewswire.com
Topics Artificial Intelligence
News headline image
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
April 18, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence
News headline image
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
April 17, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
April 10, 2024
 
Via Benzinga
News headline image
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
April 10, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
April 10, 2024
FREMONT, CA - (NewMediaWire) - April 10, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via TheNewswire.com
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
April 01, 2024
 
Via Benzinga
News headline image
Why ABVC BioPharma Stock Is Up Today ↗
March 26, 2024
ABVC BioPharma said that the licensing agreement includes the ophthalmology pipeline, including the medical device Vitargus licensed products' and clinical trial, registration, manufacturing, supply,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap